NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea · Delayed Price · Currency is KRW 555.00
-32.00 (-5.45%)
At close: Feb 27, 2026
NeoImmuneTech Company Description
NeoImmuneTech, Inc., a clinical-stage T cell-based biotechnology company, develops and sells immuno-therapeutics in Korea.
It is developing NT-I7, a clinical-stage more stable in the body, providing prolonged T cell amplification effects IL-7 for oncologic and infectious diseases; and Heterodimer hybrid Fc platform, an antibody platform technology, as well as NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier.
The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
NeoImmuneTech, Inc.
| Country | South Korea |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Luke Yun Oh |
Contact Details
Address: 2400 Research Blvd. Rockville, Maryland 20850 United States | |
| Phone | 240 801 9068 |
| Website | neoimmunetech.com |
Stock Details
| Ticker Symbol | 950220 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR8840140006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Luke Yun Oh | Chief Executive Officer |
| Tae Woo Kim | Chief Financial Officer |
| Goongjin Namgoong | Chief Operating Officer |